Clinical trials: Vinorelbine
Neoplasms, Breast
A Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive and p95HER2-positive Metastatic Breast Cancer
This is a Phase II, randomized, open-label, multi-center study evaluating the efficacy and safety of lapatinib in combination with chemotherapy versus trastuzumab in combination with chemotherapy in women with HER2-positive and…
- Trial name
- NCT01137994
- Testing
- Lapatinib, Trastuzumab, Docetaxel
- Sponsor
- GlaxoSmithKline
Metastatic Breast Cancer (MBC)
Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Metastatic Breast Cancer
This multicenter, randomized, open, parallel positive control study compares the clinical efficacy and safety of paclitaxel polymeric micelles for injection with TPC in HER2- MBC subjects who have failed ≥2 to≤4 previous…
- Trial name
- NCT06143553
- Testing
- Paclitaxel Polymeric Micelles for Injection, Eribulin Mesilate injection, Capecitabine Tablets
- Where
- 3 sites in China
- Volunteers
- 168 people
- Sponsor
- Shanghai Yizhong Pharmaceutical Co., Ltd.
Metastatic Breast Cancer
Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer
The purpose of this study is to evaluate the efficacy and safety of SKB264 in patients with unresectable locally advanced, recurrent, or metastatic HR+/HER2- breast cancer.
- Trial name
- NCT06081959
- Testing
- SKB264, Eribulin, Capecitabine
- Where
- China
- Volunteers
- 376 people
- Sponsor
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Non-small Cell Lung Cancer
Pemetrexed/Carboplatin vs Vinorelbine/Carboplatin in Patients With Completely Resected Non-small Cell Lung Cancer (NSCLC)
The main purpose of this randomized phase II trial is to evaluate the clinical feasibility and activity of administering adjuvant chemotherapy of pemetrexed/carboplatin compared with vinorelbine/carboplatin in patients with…
- Trial name
- NCT01258127
- Where
- China
- Volunteers
- 134 people
- Sponsor
- Shanghai Nancy Medical Sci-Tech Co. Ltd
Metastasis, Breast Cancer
A Study of Etirinotecan Pegol (NKTR-102) Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and Capecitabine
This is an open-label, randomized, active comparator, multicenter, international Phase 3 study of NKTR-102 versus TPC in patients with metastatic breast cancer who have stable brain metastases and have been previously treated…
- Trial name
- ATTAIN (NCT02915744)
- Testing
- NKTR-102, Eribulin, Ixabepilone
- Where
- 56 sites in United States, Australia and 8 more
- Volunteers
- 178 people
- Sponsor
- Nektar Therapeutics
Metastatic Breast Cancer in the Liver
Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Breast Cancer w/Liver Dominant Disease
The goal of this clinical trial is to learn if using a liver-directed therapy with high dose chemotherapy followed by approved cancer treatment to treat patients with breast cancer that has spread to the liver is safe and…
- Trial name
- DELUMA (NCT06875128)
- Testing
- Melphalan/HDS followed by Physician's choice of SOC (eribulin, vinorelbine, or capecitabine), Physician's choice of SOC (eribulin, vinorelbine, or capecitabine)
- Where
- 8 sites in United States, Italy and 2 more
- Volunteers
- 90 people
- Sponsor
- Delcath Systems Inc.
Triple Negative Breast Cancer
A Study of Camrelizumab in Combination With Chemotherapy Regimen Comparative Chemotherapy Regimen for Metastatic Triple-negative Breast Cancer
Approximately 104 subjects with recurrent or metastatic IM triple negative breast cancer were planned to be included in the study, and screened eligible subjects were randomly assigned in a 1:1 ratio to treatment with the…
- Trial name
- NCT05134194
- Testing
- Camrelizumab、Capecitabine/eribulin/gemcitabine/vinorelbine, Capecitabine/eribulin/gemcitabine/vinorelbine
- Where
- China
- Volunteers
- 1 people
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Lymphoma, Non-Hodgkin
BBR 2778 for Relapsed, Aggressive Non-Hodgkin's Lymphoma (NHL)
BBR 2778 is a novel aza-anthracenedione that has activity in experimental tumors and shows reduced potential for cardiotoxicity in animal models.
- Trial name
- NCT00088530
- Testing
- pixantrone, cyclophosphamide, vincristine, rituximab, prednisone, Vinorelbine, Oxalplatin, Ifosfasmide, Etoposide, Mitoxatrone, Gemcitabine or Rituximab
- Where
- 99 sites in United States, Argentina and 18 more
- Volunteers
- 140 people
- Sponsor
- CTI BioPharma
Cervical Cancer
Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer
This trial is being done to find out whether tisotumab vedotin works better than chemotherapy to treat cervical cancer. People in this study have cervical cancer that has spread to other parts of the body (metastatic) or has come…
- Trial name
- innovaTV 301 (NCT04697628)
- Testing
- tisotumab vedotin, topotecan, vinorelbine
- Where
- 211 sites in United States, Argentina and 23 more
- Volunteers
- 502 people
- Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
Metastatic HER2-positive Breast Cancer
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer
The efficacy and safety of zanidatamab in combination with physician's choice of chemotherapy compared with trastuzumab in combination with physician's choice of chemotherapy will be evaluated for the treatment of participants…
- Trial name
- NCT06435429
- Testing
- Zanidatamab, Trastuzumab, Eribulin
- Where
- 166 sites in United States, Australia and 13 more
- Volunteers
- 550 people
- Sponsor
- Jazz Pharmaceuticals
Non-Small Cell Lung Cancer (NSCLC)
A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Treatment of Physician's Choice in Subjects With Advanced Non-Small Cell Lung Cancer
This is a randomized, open-label, multicenter, Phase 3 study, comparing efficacy and safety of eribulin with TPC in subjects with advanced and disease progression following at least two prior regimens for advanced disease, which…
- Trial name
- NCT01454934
- Testing
- Eribulin, TPC -Vinorelbine,Gemcitabine,Docetaxel, and Pemetrexed
- Where
- 83 sites in United States, Australia and 12 more
- Volunteers
- 540 people
- Sponsor
- Eisai Inc.
Breast Cancer
A Study to Assess Efficacy and Safety of Pertuzumab Given in Combination With Trastuzumab and Vinorelbine in Participants With Metastatic or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer
This two-cohort, open-label, multicenter, phase 2 study will assess the safety and efficacy of pertuzumab given in combination with trastuzumab (Herceptin) and vinorelbine in first line participants with metastatic or locally…
- Trial name
- VELVET (NCT01565083)
- Testing
- Pertuzumab, Trastuzumab, Vinorelbine
- Where
- 80 sites in United States, Brazil and 5 more
- Volunteers
- 213 people
- Sponsor
- Hoffmann-La Roche
Desmoplastic Small Round Cell Tumor
CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Desmoplastic Small Round Cell Tumor
This study is being conducted to test the safety and efficacy of ramucirumab in combination with other chemotherapy in the treatment of relapsed, recurrent, or refractory desmoplastic small round cell tumor (DSRCT) in children…
- Trial name
- NCT04145349
- Testing
- Ramucirumab, Cyclophosphamide, Vinorelbine
- Where
- 22 sites in United States, Australia and 5 more
- Volunteers
- 30 people
- Sponsor
- Eli Lilly and Company
Lung Cancer
Chemotherapy and Radiation Therapy With or Without Efaproxiral in Treating Patients With Stage III Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00055887
- Testing
- carboplatin, cisplatin, efaproxiral
- Where
- 22 sites in United States, Belgium and 2 more
- Sponsor
- Spectrum Pharmaceuticals, Inc
Advanced Solid Tumors, Breast Cancer
Clinical Trial of SYS6010±SYH2051 Versus Chemotherapy in Advanced Breast Cancer and Other Solid Tumors
The study consists of two phases. Phase 1b and Phase 2. Phase 1b aims to evaluate the safety, tolerability, and preliminary efficacy of SYS6010 as a monotherapy and in combination with SYH2051, and to determine the recommended…
- Trial name
- NCT06775236
- Testing
- SYS6010 jnjection, monotherapy chemotherapy, SYH2051 tablets
- Volunteers
- 410 people
- Sponsor
- CSPC Megalith Biopharmaceutical Co.,Ltd.
Neoplasms
Afatinib and Vinorelbine in Tumours Known to Overexpress EGFR and/or HER2
To determine the maximum tolerated dose, safety, pharmacokinetics and anti-tumour efficacy of oral BIBW 2992 in combination with intravenous or oral vinorelbine
- Trial name
- NCT00906698
- Testing
- BIBW 2992 low (20mg) dosage, BIBW 2992 medium (40mg) dosage, BIBW 2992 high (50mg) dosage
- Where
- 2 sites in France
- Volunteers
- 55 people
- Sponsor
- Boehringer Ingelheim
Metastatic Breast Cancer
A Phase III Study of ESG401 for Locally Advanced or Metastatic HR+/HER2- Breast Cancer
The aim of this study is to evaluate the efficacy and safety of ESG401 in patients with unresectable locally advanced or metastatic HR+/HER2- breast cancer.
- Trial name
- NCT06383767
- Testing
- ESG401, Eribulin, capecitabine, gemcitabine or vinorelbine (Treatment of Physician's Choice)
- Where
- China
- Volunteers
- 378 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Neoplasms, Breast
Lapatinib + Vinorelbine in ErbB2 Overexpressing, First or Second Line Metastatic Breast Cancer Subjects
This is an open-label, single-arm, multi-center, Phase II study to determine the activity of vinorelbine plus lapatinib in either first- or second-line setting in women with ErbB2 overexpressing metastatic breast cancer (MBC).
- Trial name
- NCT00709618
- Testing
- Lapatinib, Vinorelbine
- Where
- 22 sites in United States
- Volunteers
- 44 people
- Sponsor
- GlaxoSmithKline
Non Small Cell Lung Cancer (NSCLC)
Study of Cisplatin/Vinorelbine +/- Cetuximab as First-line Treatment of Advanced Non Small Cell Lung Cancer (FLEX)
The purpose of this trial is to investigate the efficacy of cetuximab in combination with chemotherapy in comparison to chemotherapy alone in patients with advanced non small cell lung cancer who did not received prior…
- Trial name
- FLEX (NCT00148798)
- Testing
- cetuximab + cisplatin + vinorelbine, cisplatin + vinorelbine
- Where
- 118 sites in Argentina, Australia and 26 more
- Volunteers
- 1,861 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Neoplasms
BIBW 2992 (Afatinib) and Vinorelbine in Japanese Patients With Advanced Solid Tumours
To identify the Maximum Tolerated Dose (MTD) of afatinib in combination with vinorelbine i.v. by assessment of Dose Limiting Toxicities (DLT); To assess safety and anti-tumour efficacy and determine pharmacokinetic…
- Trial name
- NCT01214616
- Testing
- afatinib 20mg, afatinib 40mg, vinorelbine IV 25 or 20mg/m2
- Where
- 4 sites in Japan
- Volunteers
- 17 people
- Sponsor
- Boehringer Ingelheim